

# HEALTHCARE MONTHLY

**NOVEMBER 2019** 

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics

**Medical Devices** 


### **HEADLINE TRANSACTIONS**

|                     | TARGET   | ACQUIROR                       | ACQUISITION SYNOPSIS  |
|---------------------|--|--------------------------------|---|
|                     | Pharma   | ucb                            | <ul> <li>UCB SA (ENXTBR: UCB) entered into a definitive agreement to acquire Ra Pharmaceuticals, Inc. (Nasdaq: RARX) for approximately \$2.1 billion, a 93% premium</li> <li>Ra Pharmaceuticals, Inc. develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system</li> <li>UCB SA develops biopharmaceutical solutions for people living with neurology and immunology conditions</li> </ul>                            |
| BioTech / Pharma    | ACHILLION  | ALEXION                        | <ul> <li>Alexion Pharmaceuticals, Inc. (NasdaqGS: ALXN) entered into a definitive agreement to acquire Achillion Pharmaceuticals, Inc. (NasdaqGS: ACHN) for approximately \$930 million, a 73% premium</li> <li>Achillion Pharmaceuticals, Inc. develops drug therapies for immune system disorders</li> <li>Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products</li> </ul>  |
|                     | ClaxoSmithKline<br>(Rabipur/RabAvert & Encepur Vaccines) | BAVARIAN NORDIC                | <ul> <li>Bavarian Nordic A/S (CPSE: BAVA) entered into a definitive agreement to acquire the global rights of Rabipur/RabAvert and Encepur vaccines from GlaxoSmithKline (LSE: GSK) for approximately \$345 million and up to \$570 million in milestones</li> <li>Rabipur/RabAvert and Encepur Travel Vaccines are anti-rabies vaccines</li> <li>Bavarian Nordic A/S develops and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases</li> </ul> |
| Healthcare Services | <sup>≌</sup> Med <mark>Data</mark>                       | FRAZIER<br>HEALTHCARE PARTNERS | <ul> <li>Frazier Healthcare Partners entered into a definitive agreement to acquire MedData Inc. from Mednax Services, Inc. for approximately \$300 million</li> <li>MedData, Inc. provides revenue cycle management and patient lifecycle services</li> <li>Frazier Healthcare Partners, investing out of Frazier Healthcare Growth Buyout Fund IX, L.P. specializes in growth buyouts and lower middle market opportunities with an emphasis on healthcare companies</li> </ul>       |
|                     |  |                                |   |



## **HEALTHCARE GROWTH & VALUATION TRENDS**


**Health Services** 



Life Sci / Diagnostics

Medical Devices

#### **Enterprise Value / LTM EBITDA**



#### **LTM Revenue Growth**

BioTech / Pharma

6.0x


5.0x

4.0x


3.0x

2.0x


1.0x - - - -



#### LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.





#### LTM Stock Price Index

## SELECTED HEALTHCARE TRANSACTIONS

| Target  | Acquiror                    | BioTech / Pharma Transaction   |
|---|-----------------------------|--|
| Progenics<br>Pharmaceuticals,<br>Inc.   | Lantheus Holdings,<br>Inc.  | Progenics Pharmaceuticals, Inc. develops<br>pharmaceutical products and other technologies to<br>diagnose and treat cancer<br>Transaction Value: \$519.6 million |
| Over-the-counter<br>and prescription<br>pharmaceutical<br>assets in NEMEA<br>region of Takeda | Acino International<br>AG   | Portfolio of select over-the-counter and prescription<br>pharmaceutical assets<br>Transaction Value: \$200 million   |
| Biotoscana<br>Investments S.A.  | Knight Therapeutics<br>Inc. | Biotoscana Investments S.A. manufactures and sells<br>pharmaceutical products in Latin America<br>Transaction Value: \$144 million                               |

| Target                       | Acquiror          | Health Services Transaction  |
|------------------------------|-------------------|--|
| Noble<br>International, Inc. | AptarGroup, Inc.  | Noble International, Inc. provides drug delivery training,<br>patient onboarding strategies and multisensory product<br>development services for pharmaceutical companies<br>Transaction Value: \$62 million and up to \$31 million in<br>milestones |
| GSI Health, LLC              | Medecision, Inc.  | GSI Health, LLC develops a population health management platform for hospitals and health systems  |
| Remedy Chicago<br>Inc.       | The Motion Agency | Remedy Chicago Inc. provides branding and design consulting services to healthcare providers   |

| Target   | Acquiror                    | Life Sci / Diagnostics Transaction  |
|--|-----------------------------|---|
| 3DR, Inc.  | Accumen Inc.                | 3DR, Inc. provides 3D image post-processing and image reconstruction services for use in medical diagnostics  |
| Amplia Pharmaīek<br>Inc.                                 | NuChem<br>Therapeutics Inc. | Amplia PharmaTek Inc. provides enzyme and cell-based<br>assay development, compound screening, in vivo<br>pharmacology and pharmacokinetics studies |
| Phoenix Central<br>Laboratory For<br>Veterinarians, Inc. | Zoetis Inc.                 | Phoenix Central Laboratory For Veterinarians, Inc.<br>provides anatomic, pathology and microbiology<br>diagnostics                                  |

| Target                                       | Acquiror                                   | Medical Devices Transaction   |
|--|--|---|
| Providien, LLC                               | Carlisle Companies<br>Incorporated         | Providien, LLC manufactures precision components and assembled devices  |
| Midwest Products<br>And Engineering,<br>Inc. | Beecken Petty<br>O'Keefe & Company,<br>LLC | Midwest Products And Engineering, Inc. produces<br>medical carts, metal fabrication and assemblies for<br>medical and electronic OEMs |
| Xi-Tech Ltd                                  | discoverIE Group<br>plc                    | Xi-Tech Ltd manufactures specialist sensing and data acquisition modules for x-ray and optical detection applications                 |

#### Selected TM Capital Healthcare Experience







#### TM Capital's Healthcare Industry Contacts



James McLaren, Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman, Managing Director mgoldman@tmcapital.com 212.809.1419



Paul Smolevitz, Managing Director psmolevitz@tmcapital.com 212.809.1416

